ARTA
AEGR

A.R.T. Advisors’s Aegerion Pharmaceuticals AEGR Stock Holding History

A.R.T. Advisors’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-151,496
Closed -$1.53M – 1869
2015
Q4 		$1.53M Buy
151,496
+126,130
+497% +$1.52M 0.07% 384
2015
Q3 		$344K Sell
25,366
-113,750
-82% -$2.03M 0.01% 1001
2015
Q2 		$2.64M Buy
+139,116
New +$3.01M 0.09% 354
2015
Q1 		– Sell
-177,768
Closed -$3.72M – 1874
2014
Q4 		$3.72M Buy
+177,768
New +$4.48M 0.14% 188
2014
Q3 		– Sell
-74,049
Closed -$2.38M – 1705
2014
Q2 		$2.38M Buy
74,049
+22,948
+45% +$854K 0.12% 233
2014
Q1 		$2.36M Sell
51,101
-12,650
-20% -$742K 0.13% 214
2013
Q4 		$4.52M Sell
63,751
-29,804
-32% -$2.28M 0.24% 102
2013
Q3 		$8.02M Buy
93,555
+2,339
+3% +$198K 0.44% 17
2013
Q2 		$5.78M Buy
+91,216
New +$4.84M 0.19% 153

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

A.R.T. Advisors's AEGR Position: Q1 2016 in Review

A.R.T. Advisors sold out of Aegerion Pharmaceuticals (AEGR) in Q1 2016, closing a stake of 151,496 shares — an estimated $1.53M sold.

A.R.T. Advisors first reported a position in AEGR in Q2 2013 and held it in 9 quarters. The position peaked at $8.02M in Q3 2013. 101 funds tracked by Wall St. Rank hold AEGR as of Q1 2016.

  • A.R.T. Advisors reported no remaining Aegerion Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • A.R.T. Advisors sold 151,496 Aegerion Pharmaceuticals shares in Q1 2016, an estimated $1.53M.
  • A.R.T. Advisors first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 9 quarters.
  • A.R.T. Advisors's Aegerion Pharmaceuticals position peaked at $8.02M in Q3 2013.
  • 101 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q1 2016.

Based on A.R.T. Advisors's 13F filing for Q1 2016, filed 16 May 2016.